Baird analyst David Manthey maintains GMS (NYSE:GMS) with a Outperform and lowers the price target from $68 to $55.
Cantor Fitzgerald Downgrades Arena Pharmaceuticals to Neutral, Raises Price Target to $100
Cantor Fitzgerald analyst Alethia Young downgrades Arena Pharmaceuticals (NASDAQ:ARNA) from Overweight to Neutral and raises the price target from $93 to $100.